Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus SERNIVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus SERNIVO.
ARAZLO vs SERNIVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
SERNIVO (clobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply a thin layer to affected area twice daily for up to 2 weeks.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Approximately 3 hours (parent drug); clinical duration extended via formulation.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily renal excretion of inactive metabolites; <5% unchanged. Minor biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid